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Abstract
Background:  Patients with advanced cirrhosis of the liver typically display circulatory disturbance.
Haemodynamic management may be critical for avoiding and treating functional renal failure in such
patients. This study investigated the effects of plasma expansion with hyperoncotic albumin solution and
the role of static haemodynamic parameters in predicting volume responsiveness in patients with advanced
cirrhosis.
Methods: Patients with advanced cirrhosis (Child B and C) of the liver receiving albumin substitution
because of renal compromise were studied using trans-pulmonary thermodilution. Paired measurements
before and after two infusions of 200 ml of 20% albumin per patient were recorded and standard
haemodynamic parameters such as central venous pressure (CVP), mean arterial pressure (MAP), systemic
vascular resistance index (SVRI), cardiac index (CI) and derived variables were assessed, including global
end-diastolic blood volume index (GEDVI), a parameter that reflects central blood volume
Results: 100 measurements in 50 patients (33 m/17 w; age 56 years (± 8); Child-Pugh-score 12 (± 2),
serum creatinine 256 μmol (± 150) were analyzed. Baseline values suggested decreased central blood
volumes GEDVI = 675 ml/m2 (± 138) despite CVP within the normal range (11 mmHg (± 5). After infusion,
GEDVI, CI and CVP increased (682 ml/m2 (± 128) vs. 744 ml/m2 (± 171), p < 0.001; 4.3 L/min/m2 (± 1.1)
vs. 4.7 L/min/m2 (± 1.1), p < 0.001; 12 mmHg (± 6) vs. 14 mmHg (± 6), p < 0.001 respectively) and systemic
vascular resistance decreased (1760 dyn s/cm5/m2 (± 1144) vs. 1490 dyn s/cm5/m2 (± 837); p < 0.001).
Changes in GEDVI, but not CVP, correlated with changes in CI (r2 = 0.51; p < 0.001). To assess the value
of static haemodynamic parameters at baseline in predicting an increase in CI of 10%, receiver-operating-
characteristic curves were constructed. The areas under the curve were 0.766 (p < 0.001) for SVRI, 0.723
(p < 0.001) for CI, 0.652 (p = 0.010) for CVP and 0.616 (p = 0.050) for GEDVI.
Conclusion: In a substantial proportion of patients with advanced cirrhosis, plasma expansion results in
an increase in central blood volume. GEDVI but not CVP behaves as an indicator of cardiac preload,
whereas high baseline SVRI is predictive of fluid responsiveness.
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Background
Patients with advanced cirrhosis of the liver characteristi-
cally suffer from circulatory disturbance [1]. Portal hyper-
tension leads to mesenteric vasodilation. Peripheral
vascular resistance is decreased and a hyperdynamic circu-
lation ensues. Due to the pooling of blood in the splanch-
nic vessels, central blood volume is diminished [2] and
endogenous vasopressor systems are activated in compen-
sation [3]. These patients are vulnerable to further haemo-
dynamic insults and, if renal auto-regulation is
overwhelmed, acute kidney failure is a common compli-
cation [4]. This is termed hepatorenal syndrome (HRS), if
renal failure is advanced (serum creatinine > 133 μmol/l)
and if septic shock and prerenal azotaemia caused by vol-
ume losses are excluded. It negatively affects mortality [5],
even if transplantation is performed [6].
The maintenance of a stable circulation is therefore
important in cirrhotic patients. Plasma expansion with
albumin has been found to protect against renal failure in
spontaneous bacterial peritonitis [7]. It has also become a
mainstay in the treatment of HRS and a prerequisite of its
diagnosis, particularly when, according to a current con-
sensus statement, "true hypovolaemia" has to be excluded
by administration of a substantial amount (up to 100 g
daily) of albumin over two days [8]. During acute condi-
tions such as infection or haemorrhage, as well as for the
treatment of functional renal failure, parameter guided
fluid therapy may be useful for avoiding or improving rel-
ative hypovolemia, but also for avoiding potential com-
plications of fluid overload. Data on the haemodynamic
effects of an albumin infusion in cirrhotic patients, how-
ever, are scarce and it is not clear which parameters should
be employed to guide fluid therapy in cirrhotic patients.
Central venous pressure (CVP) has been shown to be of
little value in the assessment of fluid responsiveness in
critically ill patients [9-11]. In addition, elevated intra-
abdominal pressure, as seen in ascitic patients, may influ-
ence CVP [12]. It therefore is of no surprise that in a recent
study the traditional target values for CVP apparently
failed to exclude hypovolaemia in patients with HRS[13].
Pulmonary artery catheters have traditionally been used
for guiding haemodynamic interventions. Their use how-
ever remains controversial as they may be associated with
complications and their predictive value in the assessment
of fluid responsiveness is low [9,14-16]. Based on earlier
work on indicator dilution techniques for the measure-
ment of cardiac output (CO) and intra-thoracic blood vol-
umes [17,18], trans-pulmonary thermodilution
combined with continuous measurement of CO by pulse
contour analysis has in recent years been evaluated
[10,11,19]. Trans-pulmonary thermodilution has shown
some promise in guiding fluid therapy by providing
preload-associated parameters such as the global end-
diastolic volume (GEDV). A treatment protocol targeting
GEDV assessed by trans-pulmonary thermodilution
resulted in reduced need for catecholamines and less time
on mechanical ventilation in cardiac surgery patients [20].
It is, however, questionable if results from studies in non-
cirrhotic patients are to be extrapolated to cirrhotic
patients. Earlier studies found that central blood volume
in cirrhotic patients cannot be significantly expanded,
thus casting doubt on possible correlations between intra-
thoracic blood-volumes, as a measure of preload, and CO
[21,22]. To date, trans-pulmonary thermodilution has
only been evaluated in ventilated cirrhotic patients during
orthotopic transplantation of the liver [23].
The aim of this present study was to investigate the
haemodynamic response to volume loading with hyper-
oncotic albumin solution, and to compare CVP and volu-
metric measures as markers of preload, and predictors of
fluid responsiveness, in cirrhotic patients.
Methods
The institutional ethics committee (Ethikkommission des
Klinikums Rechts der Isar der Technischen Universität
München) considered the protocol part of clinical routine
and waived the need for informed written consent. Writ-
ten consent was obtained for the publication of data.
Patients
Patients with cirrhosis Child-Pugh-Class B or C and ascites
grade II or III treated in our ICU were included. Albumin
substitution was prescribed according to our internal
standards because of the risk of kidney failure as defined
by the RIFLE criteria (acute increase in serum creatinine of
1.5 times baseline or oliguria of < 0.5 ml/kg/h for at least
6 hours), or established renal failure along with indicators
of pre-renal kidney failure (fractional excretion of sodium
< 1% and no evidence of pre-existing renal impairment).
To be included, patients had to already be instrumented
with a thermodilution arterial line and a central venous
catheter. Exclusion criteria were sepsis diagnosed by clini-
cal criteria, and, if appropriate, chest x-rays, blood or urine
cultures, and current haemorrhage. Patients receiving
vasoactive or cardiotropic drugs were also excluded, as
were mechanically ventilated patients.
Albumin substitution was prescribed according to our
treatment standards for cirrhotic patients with pre-renal
kidney failure as suggested by the recent literature [8].
Haemodynamic Measurements
Patients were studied in a supine position, with zero pres-
sure at the midaxillary line. CVP was recorded at end-expi-
ration; thermodilution measurements using 15 ml of ice-
cold saline were recorded in triplicate using a commer-
cially available device (PiCCO; Pulsion Medical Systems,BMC Gastroenterology 2008, 8:39 http://www.biomedcentral.com/1471-230X/8/39
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Munich, Germany) and their average recorded. Briefly,
transpulmonary thermodilution works when a bolus of
cold saline solution is injected via a central line (usually
located in the superior vena cava) and detected down-
stream by a thermistor at the tip of the femoral arterial
catheter. CO is calculated by the analysis of the thermodi-
lution curve using the Stewart-Hamilton algorithm. Mean
transit time and exponential downslope time of the ther-
modilution curve are also analysed. The product of CO
and mean transit time is the volume of distribution of the
thermal indicator, or "intra-thoracic thermal volume"
comprising of the intra-thoracic blood volume and the
extravascular lung water. The product of CO and exponen-
tial downslope time is the "pulmonary thermal volume"
composed of the pulmonary blood volume and the
extravascular lung water. The GEDV is obtained as the dif-
ference between intra-thoracic thermal volume and pul-
monary thermal volume [24].
Values for mean arterial pressure (MAP), CVP, CO, Sys-
temic Vascular Resistance (SVR), GEDV, Stroke Volume
(SV) and Heart Rate (HR) were obtained, and, when
appropriate, indexed to an estimate of body surface area
(BSA), according to the formula of duBois, to calculate
Cardiac Index (CI), Global End-diastolic Volume Index
(GEDVI), Systemic Vascular Resistance Index (SVRI) and
Stroke Volume Index (SVI). Stroke volume divided by
pulse pressure was used as a marker for arterial compli-
ance and calculated as follows: compA = SV/(RRsys –
RRdia) [25]. Cardiac power index was calculated as CPI =
CI × MAP/451 [26].
Study Protocol
Haemodynamic measurements were performed immedi-
ately before infusion of a bolus of 200 ml 20% albumin
solution over a short time period (< 30 min). Measure-
ment of haemodynamic variables were repeated 1 hour
after the start of infusion, to allow for maximal plasma
expansion. Albumin infusions were prescribed by the
treating physician and were administered as aliquots of
200 ml 20% solution (40 g of albumin). For statistical rea-
sons, only the first two measurements after inclusion for
each patient were analysed.
Statistical analysis
Data were assessed for normal distribution using the Kol-
mogorov-Smirnov test. Normal distribution was found
for all haemodynamic parameters. Accordingly, data are
presented as mean (± SD). Haemodynamic parameters
before and after albumin infusion were compared using
Students T-test for paired samples.
Parameters displaying significant changes in univariate
analysis were evaluated for correlations with Pearson's
test.
A positive response to volume loading was defined as an
increase in CI of > 10%. This value was chosen for the fol-
lowing reasons: Previous studies investigating fluid
responsiveness have used cut-off values for CI of 10–20%
[16]. Reproducibility of measurements of CO and GEDV
have been found to be 4 ± 2% and 5 ± 2%, respectively,
and increases after plasma expansion of an amount simi-
lar to our study previously resulted in mean increases in
cardiac output of 7 – 15% [22].
Responders and non-responders were compared using the
Student T test for unpaired samples. For baseline haemo-
dynamic parameters that were significantly different
between responders and non-responders, ROC curves
were constructed to analyse their respective value to pre-
dict an increase of CI by >10% after volume loading.
Results
Baseline parameters
50 consecutive patients were included between August
2005 and January 2007. Baseline characteristics are pre-
sented in Table 1. Significant correlations were found
between baseline values of GEDVI and CI (r2 = 0.20; p =
0.001) and between baseline values of GEDVI and SVI (r2
= 0.28; p < 0.001).
Haemodynamic effects of fluid loading
Haemodynamic parameters obtained before and after 100
albumin infusions were analysed and are presented in
Table 2. In 43 cases there was an increase in CI of > 10%
after albumin infusion.
Table 1: Baseline characteristics of all patients
Age (years) 56 (± 8)
Gender (m/f) 33/17
MELD-score 28 (± 9)
Child-Pugh-score 12 (± 2)
Child-Pugh class (B/C) 10/40
Serum creatinine (μmol/l) 256 (± 150)
Fractional excretion of Sodium (%) 0.040 (± 0.026)
Creatinine clearance (ml/min) 22 (± 16)
CVP (mmHg) 11 (± 5)
GEDVI (ml/m2); (n: 680–800) 675 (± 138)
CI (L/min/m2); (n: 3–5) 4.1 (± 1.2)
SVI (ml/m2); (n: 40–60) 48 (± 13)
HR (bpm) 88 (± 20)
SVRI (dyn s/cm5/m2); (n:1700–2400) 1898 (± 1015)
compa (ml/mmHg) 1.58 (± 0.57)
MAP (mmHg) 79 (± 14)
CPI (mmHg L/min/m2) 0.71 (± 0.27)
MELD: Model of End-Stage Liver Disease; CVP: Central Venous 
Pressure; GEDVI: Global End-Diastolic Volume Index; CI: Cardiac 
Index; SVI: Stroke Volume Index; HR: Heart Rate; SVRI: Systemic 
Vascular Resistance Index; compa: Arterial Compliance; MAP: Mean 
Arterial Pressure; CPI: Cardiac Power IndexBMC Gastroenterology 2008, 8:39 http://www.biomedcentral.com/1471-230X/8/39
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Correlations between changes in haemodynamic 
parameters
Changes in CI following volume challenges showed sig-
nificant correlations with changes in GEDVI (r2 = 0.51; p
< 0.001), but not with changes in CVP (r2 0.01, p = 0.45)
or MAP (r2 = 0.01; p = 0.26). Likewise, changes in SVI were
correlated with changes in GEDVI (r2 = 0.27; p < 0.001)
but not with changes in CVP or MAP. As expected, there
was an inverse correlation between CI and SVRI (r2 = 0.21,
p < 0.001), but no correlation between CI or GEDVI and
MAP.
Predictors of fluid responsiveness
In responders CVP, GEDVI, SVI and CI were significantly
lower than in non-responders, whereas SVRI was signifi-
cantly higher (Table 3).
ROC-Curves for GEDVI, CVP and SVRI are displayed in
Figure 1. Area under the curve was greatest for SVRI (area
0.766; p < 0.001, 95%CI 0.674 – 0.859) and CI (area
0.723; p < 0.001, 95%CI 0.629 – 0.816), still significantly
better than chance (area = 0.5) for CVP (area 0.652; p =
0.010, 95%CI 0.542 – 0.761) and bordering significance
Table 2: Haemodynamic parameters before and after infusion of 200 ml of 20% albumin solution.
Before after
CVP (mmHg) 12 (± 6) 14 (± 6) p < 0.001
95% CI 1 – 3
GEDVI (ml/m2); (n: 680–800) 682 (± 128) 744 (± 171) p < 0.001
95% CI 38 – 87
CI (L/min/m2); (n: 3–5) 4.3 (± 1.1) 4.7 (± 1.1) p < 0.001
95% CI 0.3 – 0.5
SVI (ml/m2); (n: 40–60) 49 (± 12) 54 (± 13) p < 0.001
95% CI 2 – 6
HR (bpm) 89 (± 18) 90 (± 16) p = 0.816
95% CI -3 – 1
SVRI (dyn s/cm5/m2); (n: 1700–2400) 1760 (± 1144) 1490 (± 837) p < 0.001
95% CI -370 – -170
compA (ml/mmHg) 1.59 (± 0.52) 1.70 (± 0.62) p = 0.040
95% CI -0.21 – 0.02
MAP (mmHg) 78 (± 12) 80 (± 13) p = 0.310
95% CI -1 – 4
CPI (mmHg L/min/m2) 0.72 (± 0.27) 0.81 (± 0.31) p < 0.001
95% CI 0.06 – 0.13
CVP: Central Venous Pressure; GEDVI: Global End-Diastolic Volume Index; CI: Cardiac Index; SVI: Stroke Volume Index; HR: Heart Rate; SVRI: 
Systemic Vascular Resistance Index; compa: Arterial Compliance; MAP: Mean Arterial Pressure; CPI: Cardiac Power Index
Table 3: Differences in pre-infusion haemodynamic parameters between responders and non-responders
responders non-responders
CVP (mmHg) 10 (± 4) 13 (± 6) p < 0.001
95% CI 1 – 3
GEDVI (ml/m2); (n: 680–800) 638 (± 135) 714 (± 117) p < 0.001
95% CI 38 – 87
CI (L/min/m2); (n: 3–5) 3.7 (± 1.0) 4.7 (± 1.0) p < 0.001
95% CI 0.3 – 0.5
SVI (ml/m2); (n: 40–60) 45 (± 14) 54 (± 9) p < 0.001
95% CI 2 – 6
HR (bpm) 90 (± 15) 86 (± 19) p = 0.816
95% CI -3 – 1
SVRI (dyn s/cm5/m2); (n:1700–2400) 2262 (± 1323) 1390 (± 648) p < 0.001
95% CI -370 – -170
compA (ml/mmHg) 1.49 (± 1.68 (± 0.56) p = 0.040
95% CI -0.20 – 0.02
MAP (mmHg) 78 (± 13) 80 (± 13) p = 0.310
95% CI -1 – 4
CPI (mmHg L/min/m2) 0.71 (± 0.27) 0.81 (± 0.32) p < 0.001
95% CI 0.06 – 0.12
CVP: Central Venous Pressure; GEDVI: Global End-Diastolic Volume Index; CI: Cardiac Index; SVI: Stroke Volume Index; HR: Heart Rate; SVRI: 
Systemic Vascular Resistance Index; compa: Arterial Compliance; MAP: Mean Arterial Pressure; CPI: Cardiac Power IndexBMC Gastroenterology 2008, 8:39 http://www.biomedcentral.com/1471-230X/8/39
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for GEDVI (area 0.616; p = 0.050), 95%CI 0.501 – 0.731).
For SVRI a cut-off value of 1270 dyne·s/cm5/m2 discrimi-
nated between responders and non-responders (sensitiv-
ity 0.67, specificity 0.77). For CVP the best combined
sensitivity and specificity was found for a threshold value
of 10 mmHg with 0.74 and 0.54, respectively. For GEDVI
a threshold value of 680 ml/m2 had a sensitivity of 0.59
and a specificity of 0.65 for predicting a positive response
to albumin infusion.
Discussion
At baseline we found a GEDVI in the lower range of nor-
mal despite a relatively high CVP. CI was in the normal
range and SVRI at a low normal value. These findings are
in accordance with the concept suggested by the periph-
eral arterial vasodilation hypothesis on cirrhotic circula-
tory dysfunction [1]. Infusion of albumin solution
resulted in an increase in GEDVI, which correlated to an
increase in cardiac index that was larger than 10% in
almost half the cases. This is similar to what has previ-
ously been reported in fluid resuscitation of septic
patients [11]. Responders to volume loading displayed a
baseline haemodynamic pattern suggestive of lower car-
diac preload with less hyperdynamic circulation and
higher peripheral resistance.
The improvement in CI after volume therapy supports the
notion that relative central hypovolaemia contributes to
circulatory dysfunction in cirrhotic patients. After plasma
expansion with albumin we found an increase in central
blood volume. This is in contrast to the results of other
studies who failed to detect relevant changes in central
blood volume after fluid loading in patients with
advanced cirrhosis [22,27]. We believe that in these stud-
ies the possible effects were missed due to the small
number of patients included. Indeed, both studies
showed increases in central blood volume after volume
loading, however, this failed to reach statistical signifi-
cance.
In our study, baseline GEDVI correlated with baseline CI
and SVI, and GEDVI was lower in patients with a positive
response to volume loading than in those with a negative
response. Furthermore, increases in GEDVI correlated to
increases in CI and SVI, highlighting that GEDVI, evalu-
ated by trans-pulmonary thermodilution, behaves as an
indicator of preload in patients with cirrhosis. CVP was
lower in patients who responded to volume loading and
increased significantly after infusion. The volume load-
ing-induced changes, however, were not proportional to
the changes in CI and SVI, and baseline CVP did not cor-
relate with CI or SVI. This confirms previous reports and
underlines the limited value of CVP as a marker of cardiac
preload. Both parameters performed poorly as predictors
of volume responsiveness as has been previously docu-
mented in various clinical settings [16,28].
Cardiac preload is defined as myocardial wall tension at
end diastole, and, according to Laplace's law, is deter-
mined by ventricular geometry and intra-ventricular pres-
sures. Myocardial contractility depends on end-diastolic
tension of the myocardial sarcomers and the connection
between increasing preload and contractility is given in
the sigmoidal Frank-Starling curve. Without knowing the
individual myocardial properties at the moment of inter-
est, we cannot determine the position on the Frank-Star-
ling curve of any given preload condition. This explains
why good intra-individual correlations between preload
markers and CI in paired measurements may be accompa-
nied by a low predictive value of single measurements of
preload associated markers for fluid responsiveness.
Following volume challenges we observed substantial
decreases in SVRI in our patients. SVRI is dependant on
(MAP-CVP) and CI by a linear relationship. Therefore,
with constant CVP, any changes in CI must be accompa-
nied by proportional changes in SVRI, MAP, or both. In
patients with septic shock, opposite changes of a similar
relative size of both MAP and SVRI have been observed
after volume loading [11]. In contrast, we found large
decreases in SVRI with only minuscule increases in MAP.
This contrasts to a previous study on plasma expansion in
patients with spontaneous bacterial peritonitis (SBP)
Receiver operating characteristic curves for systemic vascu- lar resistance index (continuous line), central venous pres- sure (dotted line) and global and-diastolic volume index  (broken line) Figure 1
Receiver operating characteristic curves for systemic 
vascular resistance index (continuous line), central 
venous pressure (dotted line) and global and-diastolic 
volume index (broken line). The diagonal line is the line 
of no-discrimination.BMC Gastroenterology 2008, 8:39 http://www.biomedcentral.com/1471-230X/8/39
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[29]. Here the authors described an increase in peripheral
vascular resistance after treatment of SBP with antibiotics
and albumin. They hypothesized that this may be due to
the pharmacological action of albumin as a scavenger of
nitric oxide, thus reducing the vasodilatory properties of
plasma. However, haemodynamic measurements in this
study were days apart and the increased vasotonus, may
have been due to reduced septic vasodilation. In our study
cohort, care was taken to select patients without infection
or haemorrhage, so that any related confounding factors
were avoided.
Whereas MAP was not different between the patients who
responded to volume loading and those who did not,
SVRI was significantly and by a large proportion higher in
responders when compared to non-responders. However,
CI was significantly lower in responders than in non-
responders. Pre-infusion values of SVRI (and CI) were pre-
dictive of volume responsiveness in our patients. As sug-
gested previously [30], this may indicate that in a
proportion of patients with cirrhotic circulatory dysfunc-
tion, relative central hypovolaemia, resulting in further
activation of endogenous vasopressor systems to main-
tain MAP at the cost of high peripheral resistance, may
contribute to impaired cardiac output, despite what is
essentially a hyperdynamic circulation. Volume therapy
may thus decrease vasopressor activation, and may lead to
decreased levels of endogenous vasopressors such as nore-
pinephrine, renin and angiotensin, as has been described
previously [22]. Renal dysfunction in cirrhosis deterio-
rates along a continuum starting with an impaired capac-
ity to excrete sodium and free water leading to an
oedematous state with increased plasma volume and
ascites, to pre-renal failure and, finally, irreversible tubu-
lar damage. According to current understanding, an
important etiologic factor is elevated levels of vasocon-
strictors affecting the renal microcirculation, narrowing
the kidneys' capacity to cope with additional haemody-
namic insults. Volume management may be relevant to
the prevention and treatment of functional renal failure in
cirrhosis. Recent studies on vasopressor therapy in HRS
highlight the importance of adequate volume status.
Whereas it had previously been shown that albumin was
necessary for the beneficial effect of terlipressin [31], a
recent study by Alessandria et al. showed that a substantial
number of patients included in a study on treatment of
HRS responded to plasma expansion alone when it was
tailored according to CVP instead of using the usual fixed-
dose regimen [13]. In this study the aim was a CVP of 10
– 15 mmHg. In our study, 33% of patients with a CVP
greater than 10 mmHg and 24% of patients a CVP of over
> 15 mmHg still responded to albumin infusion with a
further increase in CI. Consequently, neither CVP nor
GEDVI should be recommended as parameters to direct
fluid resuscitation in cirrhotic patients with pre-renal kid-
ney failure.
In ventilated patients, dynamic parameters such as pulse
pressure variation or stroke volume variation have shown
much better predictive power for assessing fluid respon-
siveness [28]. However, the majority of cirrhotic patients
at risk of renal failure are breathing spontaneously and
these circumstances, dynamic parameters are not applica-
ble. A time honoured method for the assessment of fluid
responsiveness, "passive leg raising" (PLR) [32], has
recently gained renewed interest in the intensive care set-
ting. PLR generates a transient increase in venous return.
The immediate haemodynamic response of mean blood
flow to this manoeuvre, assessed by methods such as
oesophageal Doppler [33] or trans-thoracic echocardiog-
raphy [34], has been used to estimate fluid responsive-
ness. The recently published method of PLR is difficult to
apply in the intensive care setting, because a fixed angle of
the hips is required throughout the procedure and the
whole bed must be tilted instantaneously by 45°. Cir-
rhotic patients may react differently to tilting than other
patients or normal controls [35], and the elevated intra-
abdominal pressure of ascitic patients may also affect PLR-
induced blood transfer [36]. Therefore, PLR may give dif-
ferent results in cirrhotic patients. This has not to our
knowledge been evaluated.
Without static parameters predictive of fluid responsive-
ness, but a variety of monitoring tools capable of provid-
ing data on CI and MAP, iterative protocols of fluid
challenges may offer the possibility of increasing cardiac
output in patients with reduced effective intravascular vol-
ume [14]. Whether this translates to improved kidney
function in cirrhotic patients with renal failure should be
evaluated in future studies.
The obvious limitations of our study are the uncontrolled
design and the use of albumin solution instead of crystal-
loid solutions for the volume challenge. Hyperoncotic
albumin solution acts as a plasma expander and, in addi-
tion, has distinct pharmacological properties.
Conclusion
In contrast to earlier studies we have observed a signifi-
cant increase in central blood volume and CI after albu-
min infusion in a substantial proportion of patients with
advanced cirrhosis. In contrast to CVP, GEDVI behaved as
a preload indicator, but neither parameter was able to pre-
dict fluid responsiveness with acceptable accuracy. After
albumin infusion there were no relevant changes in MAP,
but large decreases in SVRI. Pre-infusion SVRI and CI dis-
criminated between patients with and without a positive
response in CI to volume loading. Circulatory dysfunction
in cirrhotic patients with pre-renal kidney failure may beBMC Gastroenterology 2008, 8:39 http://www.biomedcentral.com/1471-230X/8/39
Page 7 of 8
(page number not for citation purposes)
amenable to plasma expansion and future trials to evalu-
ate fluid resuscitation strategies in these patients are war-
ranted.
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